Figure 3 Cumulative Proportion of Patients Who Remained Free of GERD Relapse --- Protocol NRRK-ODD



APPEARS THIS WAY
ON ORIGINAL

Table 4 Life Table Survival Estimates of Relapse --- Protocol NRRK-ODD

Life Table Survival Estimates of Relapse
Pairwise Comparison
Rabeprazole 10 mg QAM vs. Rabeprazole 20 mg QAM

Interval (weeks) (Lower, Upper)		Number with Relapse	Number Censored	Effective Sample Size	Probability of No Relapse	Probability of Relapse
Rabeprazole 10 mg QAM (N=66)						
0	8	11	6	63	1.000	0.000
8	17	3	0	49	0.825	0.175
17	34	1	1	46	0.775	0.225
34	43	1	3	43	0.758	0.242
43	52	2	12	34	0.740	0.260
52		0	25	13	0.696	0.304
Rabeprazole 20 mg QAM (N=67)						
0	8	3	3	66	1.000	0.000
8	17	2	1	61	0.954	0.046
17	34	0	4	56	0.923	0.077
34	43	1	0	54	0.923	0.077
43	52	0	16	45	0.906	0.094
52		1	36	19	0.906	0.094
Placebo (N=70)						
0	8	38	4	68	1.000	0.000
8	17	4	2	27	0.441	0.559
17	34	6	1	22	0.376	0.624
34	43	1	0	15	0.271	0.729
43	52	1	5	12	0.253	0.747
52		0	8	4	0.231	0.769

Comparison	Log rank p-value	Wilcoxon p-value
Rab 10 mg QAM vs Placebo	0.0001	0.0001
Rab 20 mg QAM vs Placebo	0.0001	0.0001
Rab 10 mg QAM vs Rab 20 mg QAM	0.0097	0.0085

Copied from Tables TRRK-Odd 6.3.1 – 6.3.3.

APPEARS THIS WAY
ON ORIGINAL

Table 5 Summary of Relapse Rates for GERD Heartburn Frequency --- Protocol NRRK-ODD

Summary of Relapse Rates for GERD Heartburn Frequency

Week	Rabeprazole 10 mg QAM	Rabeprazole 20 mg QAM	Placebo QAM	p-value[a] Placebo vs. Rabeprazole 10 mg	p-value[a] Placebo vs. Rabeprazole 20 mg	p-value[a] Rabeprazole 10 mg vs. 20 mg
4	9/55 (16%)	6/52 (12%)	26/45 (58%)	<0.001	<0.001	0.373
13	12/55 (22%)	6/52 (12%)	28/45 (62%)	<0.001	<0.001	0.307
26	13/55 (24%)	4/52 (8%)	29/45 (64%)	<0.001	<0.001	0.061
39	12/55 (22%)	8/52 (15%)	28/45 (62%)	<0.001	<0.001	0.329
52	9/55 (16%)	4/52 (8%)	28/45 (62%)	<0.001	<0.001	0.256

Six patients were not evaluable for efficacy because of study drug misrandomization.

Relapse in GERD Heartburn Frequency was defined as 2 (several), 3 (many), or 4 (continual); patients with baseline grades of 2 (several), 3 (many), or 4 (continual) were excluded from the analysis.

[a] Pairwise treatment p-value is adjusted for investigator, obtained using the Cochran-Mantel-Haenszel statistic.

Cross Reference: Table 4.2

Table 6 Summary of Relapse Rates for GERD Daytime Heartburn --- Protocol NRRK-ODD

Summary of Relapse Rates for GERD Daytime Heartburn

Week	Rabeprazole 10 mg QAM	Rabeprazole 20 mg QAM	Placebo QAM	p-value[a] Placebo vs. Rabeprazole 10 mg	Placebo vs. Rabeprazole 20 mg	Rabeprazole 10 mg vs. 20 mg
4	2/64 (3%)	2/62 (3%)	17/61 (28%)	<0.001	<0.001	0.878
13	4/64 (6%)	1/62 (2%)	18/61 (30%)	0.002	<0.001	0.151
26	4/64 (6%)	3/62 (5%)	20/61 (33%)	0.001	<0.001	0.326
39	5/64 (8%)	3/62 (5%)	18/61 (30%)	0.006	<0.001	0.186
52	3/64 (5%)	2/62 (3%)	19/61 (31%)	<0.001	<0.001	0.324

Six patients were not evaluable for efficacy because of study drug misrandomization.

Relapse in GERD Daytime Heartburn Severity was defined as 2 (moderate), 3 (severe), or 4 (terrible); patients with baseline grades of 2 (moderate), 3 (severe), or 4 (terrible) were excluded from the analysis.

[a] Pairwise treatment p-value is adjusted for investigator; obtained using the Cochran-Mantel-Haenszel statistic.

Cross Reference: Table 5.2

Table 7 Summary of Relapse Rates for GERD Nighttime Heartburn --- Protocol NRRK-ODD

Summary of Relapse Rates for GERD Nighttime Heartburn

Week	Rabeprazole 10 mg QAM	Rabeprazole 20 mg QAM	Placebo QAM	p-value[a] Placebo vs. Rabeprazole 10 mg	p-value[a] Placebo vs. Rabeprazole 20 mg	p-value[a] Rabeprazole 10 mg vs. 20 mg
4	5/61 (8%)	1/61 (2%)	18/56 (32%)	0.005	<0.001	0.150
13	4/61 (7%)	0/61 (0%)	16/56 (29%)	0.002	<0.001	0.047
26	7/61 (11%)	1/61 (2%)	20/56 (36%)	0.006	<0.001	0.036
39	5/61 (8%)	4/61 (7%)	18/56 (32%)	0.003	<0.001	0.826
52	4/61 (7%)	1/61 (2%)	19/56 (34%)	<0.001	<0.001	0.187

Six patients were not evaluable for efficacy because of study drug misrandomization.

Relapse in GERD Nighttime Heartburn Severity was defined as 2 (moderate), 3 (severe), or 4 (terrible); patients with baseline grades of 2 (moderate), 3 (severe), or 4 (terrible) were excluded from the analysis.

[a] Pairwise treatment p-value is adjusted for investigator; obtained using the Cochran-Mantel-Haenszel statistic.

Cross Reference: Table 6.2

Table 8 Summary of Relapse Rates in Patients' Overall Well-Being --- Protocol NRRK-ODD

Summary of Relapse Rates in Patients' Overall Well-Being
Intent to Treat

Week	Rabeprazole 10 mg QAM	Rabeprazole 20 mg QAM	Placebo QAM	p-value[a] Placebo vs. Rabeprazole 10 mg	p-value[a] Placebo vs. Rabeprazole 20 mg	p-value[a] Rabeprazole 10 mg vs. 20 mg
4	4/59 (7%)	3/58 (5%)	12/56 (21%)	0.033	0.020	0.431
13	7/59 (12%)	2/58 (3%)	13/56 (23%)	0.126	0.004	0.048
26	7/59 (12%)	4/58 (7%)	15/56 (27%)	0.055	0.009	0.199
39	8/59 (14%)	6/58 (10%)	14/56 (25%)	0.103	0.037	0.446
52	7/59 (12%)	5/58 (9%)	15/56 (27%)	0.048	0.024	0.359

Six patients were not evaluable for efficacy because of study drug misrandomization.
Relapse in patients' Overall Physical Well-Being was defined as 2 (fair), 3 (poor), or 4 (very poor); patients with baseline grades of 2 (fair), 3 (poor), or 4 (very poor) were excluded from the analysis.
[a] Pairwise treatment p-value is adjusted for investigator; obtained using the Cochran-Mantel-Haenszel statistic.
Cross Reference: Table 7.2

Table 9 Summary of Antacid Use (Doses per Day) — Protocol NRRK-ODD

Summary of Antacid Use (Doses per Day)

Week	Rabeprazole 10 mg QAM	Rabeprazole 20 mg QAM	Placebo QAM	p-value[a] Placebo vs. Rabeprazole 10 mg	Placebo vs. Rabeprazole 20 mg	Rabeprazole 10 mg vs. 20 mg
Week 4 Change from Baseline						
n	56	56	59			
Mean	-0.10	-0.51	0.74	<0.001	<0.001	0.385
S.E.	0.175	0.269	0.193			
Week 13 Change from Baseline						
n	45	49	25			
Mean	-0.24	-0.47	0.64	<0.001	<0.001	0.742
S.E.	0.141	0.233	0.362			
Week 26 Change from Baseline						
n	42	49	17			
Mean	-0.24	-0.65	0.66	<0.001	<0.001	0.741
S.E.	0.157	0.310	0.196			
Week 39 Change from Baseline						
n	35	45	15			
Mean	-0.39	-0.47	0.80	<0.001	<0.001	0.938
S.E.	0.169	0.272	0.226			
Week 52 Change from Baseline						
n	34	43	14			
Mean	-0.46	-0.24	0.59	<0.001	<0.001	0.414
S.E.	0.167	0.140	0.200			

Six patients were not evaluable for efficacy because of study drug misrandomization.

[a] Pairwise treatment p-value is adjusted for baseline value and investigator; obtained from ANCOVA (baseline value, investigator and treatment effects).

Cross Reference: Table 9 and Patient Data Listing 8

APPEARS THIS WAY
ON ORIGINAL

Table 10 Summary of Demographic and Baseline Characteristics ---- Protocol NRRK-EVEN

Characteristic	Placebo (N=99)	Rabeprazole 10 mg (N= 95)	Rabeprazole 20 mg (N=94)	Total (N =288)	Between Treatment p-value[a]
Sex					0.859
Male	66 (67%)	66 (69%)	62 (66%)	194 (67%)	
Female	33 (33%)	29 (31%)	32 (34%)	94 (33%)	
Race					0.223
Caucasian	93 (94%)	88 (93%)	85 (90%)	266 (92%)	
African	3 (3%)	3 (3%)	8 (9%)	14 (5%)	
Other	3 (3%)	4 (4%)	1 (1%)	8 (3%)	
Age (yr)					0.539
Mean	50.8	51.4	52.9	51.7	
S.D.	13.1	14.0	14.8	14.0	
Minimum	21	19	23	19	
Maximum	76	81	85	85	
Tobacco Consumption					0.468
No	66 (67%)	69 (73%)	70 (74%)	205 (71%)	
Yes	33 (33%)	26 (27%)	24 (26%)	83 (29%)	
Alcohol Consumption					0.420
No	62 (63%)	56 (59%)	64 (68%)	182 (63%)	
Yes	37 (37%)	39 (41%)	30 (32%)	106 (37%)	
Caffeine Consumption					0.219
No	27 (27%)	16 (17%)	21 (22%)	64 (22%)	
Yes	72 (73%)	78 (82%)	72 (77%)	222 (77%)	
Missing	0 (0%)	1 (1%)	1 (1%)	2 (<1%)	

Copied from Table NRRK-Even 6.1, page 71 Vol. 200

[a] Treatment p-value is adjusted for investigator; obtained using stratified Mantel-Haenszel Chi-Square for categorical variables or using ANOVA (investigator and treatment effects) for continuous variables.

Table 10 Summary of Demographic and Baseline Characteristics ---- NRRK-EVEN (continued)

Characteristic	Placebo (N=99)	Rabeprazole 10 mg (N= 95)	Rabeprazole 20 mg (N=94)	Total (N =288)	Between Treatment p-value[a]
Antacid Use					0.067
No	75 (76%)	63 (66%)	75 (80%)	213 (74%)	
Yes	24 (24%)	32 (34%)	18 (19%)	74 (26%)	
Missing	0 (0%)	0 (0%)	1 (1%)	1 (<1%)	
Number of Doses of Antacid Used per Day (based on average of last three days)					0.041
n	99	95	93	207	
Mean	0.46	0.87	0.44	0.76	
S.D.	1.16	1.63	1.14	1.99	
Minimum	0	0	0	0	
Maximum	8	8	6	18	
Baseline Endoscopy Modified Hetzel-Dent Esophagitis Grade					0.857
n	99	93	93	203	
0	73 (74%)	64 (69%)	65 (70%)	151(74%)	
1	26 (26%)	29 (31%)	28 (30%)	52 (26%)	
2+[b]	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
Baseline GERD Heartburn Frequency Grade					0.347
n	90	93	93	285	
0=None	56 (57%)	42 (45%)	54 (58%)	152 (53%)	
1=Few	23 (23%)	30 (32%)	18 (19%)	71 (25%)	
2=Several	6 (6%)	7 (8%)	8 (9%)	21 (7%)	
3=Many	4 (4%)	3 (3%)	4 (4%)	11 (4%)	
4=Continual	9 (9%)	10 (11%)	9 (10%)	28 (10%)	
Missing	1 (1%)	1 (1%)	0 (0%)	2 (1%)	

Copied from Table NRRK-Even 6.1, page 72, Vol. 200.

[a] Treatment p-value is adjusted for investigator; obtained using stratified Mantel-Haenszel Chi-Square for categorical variables or using ANOVA (investigator and treatment effects) for continuous variables.

[b] 2+ combines Grade 2, 3, 4 and 5.

Table 11 Kaplan-Meier Chance of GERD Relapse Over Time — Protocol NRRK-EVEN

Kaplan-Meier Chance of GERD Relapse Over Time

	Rabeprazole 10 mg QAM	Rabeprazole 20 mg QAM	Placebo QAM
Total Number of Patients	93	93	99
Total Number of Patients with Relapse	21	13	70
Total Number of Patients Censored	72	80	29
Kaplan-Meier Probability of Relapse at Day 365[a]	21%	13%	74%
Mean Time to Relapse (Days)	321.3	341.3	86.6
Rabeprazole 10 mg vs. Placebo			
DF=1			
Chi-Square *= 54.688			
p-value<0.0001			
Chi-Square **= 54.934			
p-value <0.0001			
Rabeprazole 20 mg vs. Placebo			
DF=1			
Chi-Square *= 67.423			
p-value<0.0001			
Chi-Square **= 66.823			
p-value <0.0001			
Rabeprazole 10 mg vs. 20 mg			
DF=1			
Chi-Square *= 2.155			
p-value= 0.1421			
Chi-Square **= 2.144			
p-value = 0.1432			

[a] The corresponding probabilities of remaining healed at Day 365 are 79% for rabeprazole sodium 10 mg, 87% for rabeprazole sodium 20 mg, and 26% for placebo-treated patients.
*Log-rank test for censored data: p-value adjusted for investigator.
** Wilcoxon test; p-value adjusted for investigator.
Cross Reference: Table 3.4

APPEARS THIS WAY
ON ORIGINAL

Figure 12 Cumulative Proportion of Patients Who Remained Free of GERD Relapse --- Protocol NRRK-EVEN



Table 13 Life Table Survival Estimates of Relapse --- Protocol NRRK-EVEN

Life Table Survival Estimates of Relapse
Pairwise Comparison
Rabeprazole 10 mg QAM vs. Rabeprazole 20 mg QAM

Interval (weeks) (Lower, Upper)		Number with Relapse	Number Censored	Effective Sample Size	Probability of No Relapse	Probability of Relapse
Rabeprazole 10 mg QAM (N=93)						
0	8	10	3	92	1.000	0.000
8	17	3	3	79	0.891	0.109
17	34	1	7	71	0.857	0.143
34	43	1	0	66	0.845	0.156
43	52	3	15	58	0.832	0.168
52		3	44	25	0.788	0.212
Rabeprazole 20 mg QAM (N=93)						
0	8	6	3	92	1.000	0.000
8	17	3	3	83	0.934	0.066
17	34	1	3	77	0.900	0.100
34	43	0	5	72	0.889	0.111
43	52	0	27	56	0.889	0.111
52		3	39	23	0.889	0.111
Placebo (N=99)						
0	8	59	5	97	1.000	0.000
8	17	7	1	35	0.389	0.611
17	34	4	1	27	0.310	0.690
34	43	0	2	21	0.263	0.737
43	52	0	4	18	0.263	0.737
52		0	16	8	0.263	0.737

Comparison	Log rank p-value	Wilcoxon p-value
Rab 10 mg QAM vs Placebo	0.0001	0.0001
Rab 20 mg QAM vs Placebo	0.0001	0.0001
Rab 10 mg QAM vs Rab 20 mg QAM	0.2223	0.1629

Copied from Tables TRRK-Even 6.3.1 – 6.3.3.

Table 14 Summary of Relapse Rates for GERD Heartburn Frequency --- Protocol NRRK-EVEN

Summary of Relapse Rates for GERD Heartburn Frequency

Week	Rabeprazole 10 mg QAM	Rabeprazole 20 mg QAM	Placebo QAM	p-value[a] Placebo vs. Rabeprazole 10 mg	p-value[a] Placebo vs. Rabeprazole 20 mg	p-value[a] Rabeprazole 10 mg vs. 20 mg
4	19/72 (26%)	20/72 (28%)	58/79 (73%)	<0.001	<0.001	0.794
13	18/72 (25%)	16/72 (22%)	57/79 (72%)	<0.001	<0.001	0.539
26	22/72 (31%)	14/72 (19%)	58/79 (73%)	<0.001	<0.001	0.262 NO
39	22/72 (31%)	18/72 (25%)	57/79 (72%)	<0.001	<0.001	0.506
52	22/72 (31%)	15/72 (21%)	57/79 (72%)	<0.001	<0.001	0.392

Three patients were not evaluable for efficacy because of study drug misrandomization.

Relapse in GERD Heartburn Frequency was defined as 2 (several), 3 (many), or 4 (continual); patients with baseline grades of 2 (several), 3 (many), or 4 (continual) were excluded from the analysis.

[a] Pairwise treatment p-value is adjusted for investigator and baseline value, obtained using the Cochran-Mantel-Haenszel statistic.

Cross Reference: Table 4.2

Table 15 Summary of Relapse Rates for GERD Daytime Heartburn --- Protocol NRRK-EVEN

Summary of Relapse Rates for GERD Daytime Heartburn

Week	Rabeprazole 10 mg QAM	Rabeprazole 20 mg QAM	Placebo QAM	p-value[a] Placebo vs. Rabeprazole 10 mg	Placebo vs. Rabeprazole 20 mg	Rabeprazole 10 mg vs. 20 mg
4	9/84 (11%)	5/87 (6%)	24/90 (27%)	0.008	0.002	0.228
13	10/84 (12%)	5/87 (6%)	22/90 (24%)	0.021	0.001	0.159
26	9/84 (11%)	3/87 (3%)	24/90 (27%)	0.008	<0.001	0.095
39	10/84 (12%)	5/87 (6%)	24/90 (27%)	0.013	<0.001	0.168
52	11/84 (13%)	5/87 (6%)	23/90 (26%)	0.040	<0.001	0.102

Three patients were not evaluable for efficacy because of study drug misrandomization.

Relapse in GERD Daytime Heartburn Severity was defined as 2 (moderate), 3 (severe), or 4 (terrible); patients with baseline grades of 2 (moderate), 3 (severe), or 4 (terrible) were excluded from the analysis.

[a] Pairwise treatment p-value is adjusted for investigator and baseline value; obtained using the Cochran-Mantel-Haenszel statistic.

Cross Reference: Table 5.2

Table 16 Summary of Relapse Rates for GERD Nighttime Heartburn --- Protocol NRRK-EVEN

Summary of Relapse Rates for GERD Nighttime Heartburn

Week	Rabeprazole 10 mg QAM	Rabeprazole 20 mg QAM	Placebo QAM	p-value[a] Placebo vs. Rabeprazole 10 mg	p-value[a] Placebo vs. Rabeprazole 20 mg	p-value[a] Rabeprazole 10 mg vs. 20 mg
4	11/80 (14%)	7/87 (8%)	23/87 (26%)	0.086	0.004	0.247
13	11/80 (14%)	3/87 (3%)	24/87 (28%)	0.022	<0.001	0.020
26	14/80 (18%)	6/87 (7%)	24/87 (28%)	0.205	<0.001	0.010
39	14/80 (18%)	8/87 (9%)	23/87 (26%)	0.138	0.003	0.125
52	13/80 (16%)	8/87 (9%)	23/87 (26%)	0.132	0.003	0.078

Three patients were not evaluable for efficacy because of study drug misrandomization.

Relapse in GERD Nighttime Heartburn Severity was defined as 2 (moderate), 3 (severe), or 4 (terrible); patients with baseline grades of 2 (moderate), 3 (severe), or 4 (terrible) were excluded from the analysis.

A Pairwise treatment p-value is adjusted for investigator and baseline value; obtained using the Cochran-Mantel-Haenszel statistic.

Cross Reference: Table 6.2

Table 17 Summary of Relapse Rates in Patients' Overall Well-Being --- Protocol NRRK-EVEN

Summary of Relapse Rates in Patients' Overall Well-Being
Intent-to-Treat

Week	Rabeprazole 10 mg QAM	Rabeprazole 20 mg QAM	Placebo QAM	p-value[a] Placebo vs. Rabeprazole 10 mg	Placebo vs. Rabeprazole 20 mg	Rabeprazole 10 mg vs. 20 mg
4	15/80 (19%)	7/84 (8%)	25/86 (29%)	0.142	<0.001	0.042
13	13/80 (16%)	7/84 (8%)	22/86 (26%)	0.234	0.008	0.068
26	13/80 (16%)	8/84 (10%)	25/86 (29%)	0.049	0.002	0.135
39	15/80 (19%)	8/84 (10%)	24/86 (28%)	0.176	0.005	0.101
52	15/80 (19%)	7/84 (8%)	25/86 (29%)	0.133	0.001	0.037

Three patients were not evaluable for efficacy because of study drug misrandomization.

Relapse in Patients' Overall Physical Well-Being was defined as 2 (fair), 3 (poor), or 4 (very poor); patients with baseline grades of 2 (fair), 3 (poor), or 4 (very poor) were excluded from the analysis.

[a] Pairwise treatment p-value is adjusted for investigator and baseline value; obtained using the Cochran-Mantel-Haenszel statistic.

Cross Reference: Table 7.2

Table 18 Summary of Antacid Use (Doses per Day) --- Protocol NRRK-EVEN

Summary of Antacid Use (Doses per Day)

Week	Rabeprazole 10 mg QAM	Rabeprazole 20 mg QAM	Placebo QAM	p-value[a] Placebo vs. Rabeprazole 10 mg	p-value[a] Placebo vs. Rabeprazole 20 mg	p-value[a] Rabeprazole 10 mg vs. 20 mg
Week 4 Change from Baseline						
n	86	86	96			
Mean	-0.44	-0.18	0.86	<0.001	<0.001	0.394
S.E.	0.167	0.116	0.170			
Week 13 Change from Baseline						
n	73	78	36			
Mean	-0.55	-0.23	0.38	<0.001	<0.001	0.626
S.E.	0.197	0.129	0.236			
Week 26 Change from Baseline						
n	72	71	28			
Mean	-0.65	-0.20	-0.03	0.002	0.010	0.455
S.E.	0.187	0.112	0.226			
Week 39 Change from Baseline						
n	67	66	20			
Mean	-0.79	-0.22	-0.06	0.175	0.447	0.378
S.E.	0.208	0.149	0.159			
Week 52 Change from Baseline						
n	59	62	18			
Mean	-0.78	-0.31	-0.11	0.042	0.014	0.559
S.E.	0.213	0.141	0.162			

Three patients were not evaluable for efficacy because of study drug misrandomization.

[a] Pairwise treatment p-value is adjusted for baseline value and investigator; obtained from ANCOVA (baseline value, investigator, and treatment effects).

Cross Reference: Table 9 and Patient Data Listing 8